The invention relates to an immunoenzymatic method for the quantification of protein CETP in plasma, which requires the utilization of fusion protein GST/CETP, the synthetic peptide CETP 11486-S496 and polyclonal antibody anti-CEPT 11486-S496. The method is used in the study of pathologies involving alterations in the CETP levels in plasma or in seric lipids and makes it possible to detect, evaluate and follow-up patients suffering from dyslipidemia and/or risk of altergenesis.